These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
493 related articles for article (PubMed ID: 26191272)
41. Increased expression of microRNA-301a in nonsmall-cell lung cancer and its clinical significance. Shi YK; Zang QL; Li GX; Huang Y; Wang SZ J Cancer Res Ther; 2016; 12(2):693-8. PubMed ID: 27461635 [TBL] [Abstract][Full Text] [Related]
42. Overexpression of MicroRNA-221 is associated with poor prognosis in non-small cell lung cancer patients. Zhang Y; Zhao Y; Sun S; Liu Z; Zhang Y; Jiao S Tumour Biol; 2016 Aug; 37(8):10155-60. PubMed ID: 26831656 [TBL] [Abstract][Full Text] [Related]
43. Prognostic impact of vascular and lymphovascular invasion in early lung cancer. Al-Alao BS; Gately K; Nicholson S; McGovern E; Young VK; O'Byrne KJ Asian Cardiovasc Thorac Ann; 2014 Jan; 22(1):55-64. PubMed ID: 24585645 [TBL] [Abstract][Full Text] [Related]
44. Aberrant expression of microRNA-26b and its prognostic potential in human cervical cancer. Luo M; Shen D; Wang W; Xian J Int J Clin Exp Pathol; 2015; 8(5):5542-8. PubMed ID: 26191262 [TBL] [Abstract][Full Text] [Related]
46. Decreased expression of microRNA-375 in nonsmall cell lung cancer and its clinical significance. Li Y; Jiang Q; Xia N; Yang H; Hu C J Int Med Res; 2012; 40(5):1662-9. PubMed ID: 23206448 [TBL] [Abstract][Full Text] [Related]
47. Clinicopathologic features and prognostic implications of Gankyrin protein expression in non-small cell lung cancer. Wang WP; Yan XL; Li WM; Ni YF; Zhao JB; Lu Q; Wang XJ; Sun Y; Chen P; Yan BY; Cui Y; Zhang ZP; Li XF Pathol Res Pract; 2015 Dec; 211(12):939-47. PubMed ID: 26554593 [TBL] [Abstract][Full Text] [Related]
48. Serum miR-19a expression correlates with worse prognosis of patients with non-small cell lung cancer. Lin Q; Chen T; Lin Q; Lin G; Lin J; Chen G; Guo L J Surg Oncol; 2013 Jun; 107(7):767-71. PubMed ID: 23609137 [TBL] [Abstract][Full Text] [Related]
49. Identification of miR‑124a as a novel diagnostic and prognostic biomarker in non‑small cell lung cancer for chemotherapy. Luo P; Yang Q; Cong LL; Wang XF; Li YS; Zhong XM; Xie RT; Jia CY; Yang HQ; Li WP; Cong XL; Xia Q; Fu D; Zeng QH; Ma YS Mol Med Rep; 2017 Jul; 16(1):238-246. PubMed ID: 28534972 [TBL] [Abstract][Full Text] [Related]
50. Downregulation of miR-361-5p associates with aggressive clinicopathological features and unfavorable prognosis in non-small cell lung cancer. Zhuang ZL; Tian FM; Sun CL Eur Rev Med Pharmacol Sci; 2016 Dec; 20(24):5132-5136. PubMed ID: 28051257 [TBL] [Abstract][Full Text] [Related]
51. Expression and clinical evidence of miR-494 and PTEN in non-small cell lung cancer. Wang J; Chen H; Liao Y; Chen N; Liu T; Zhang H; Zhang H Tumour Biol; 2015 Sep; 36(9):6965-72. PubMed ID: 25861022 [TBL] [Abstract][Full Text] [Related]
52. MiR-181a inhibits non-small cell lung cancer cell proliferation by targeting CDK1. Shi Q; Zhou Z; Ye N; Chen Q; Zheng X; Fang M Cancer Biomark; 2017 Dec; 20(4):539-546. PubMed ID: 28946554 [TBL] [Abstract][Full Text] [Related]
53. Serum microRNA-135a downregulation as a prognostic marker of non-small cell lung cancer. Zhang YK; Sun B; Sui G Genet Mol Res; 2016 Aug; 15(3):. PubMed ID: 27525941 [TBL] [Abstract][Full Text] [Related]
54. Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05). Joerger M; Baty F; Früh M; Droege C; Stahel RA; Betticher DC; von Moos R; Ochsenbein A; Pless M; Gautschi O; Rothschild S; Brauchli P; Klingbiel D; Zappa F; Brutsche M Lung Cancer; 2014 Aug; 85(2):306-13. PubMed ID: 24928469 [TBL] [Abstract][Full Text] [Related]
55. Association of p53/p21 expression and cigarette smoking with tumor progression and poor prognosis in non-small cell lung cancer patients. Xie D; Lan L; Huang K; Chen L; Xu C; Wang R; Shi Y; Wu X; Wang L; Liu Y; Lu B Oncol Rep; 2014 Dec; 32(6):2517-26. PubMed ID: 25333671 [TBL] [Abstract][Full Text] [Related]
56. Genetic variants in genes of tricarboxylic acid cycle key enzymes are associated with prognosis of patients with non-small cell lung cancer. Guo X; Li D; Wu Y; Chen Y; Zhou X; Wang X; Huang X; Li X; Yang H; Xing J Lung Cancer; 2015 Feb; 87(2):162-8. PubMed ID: 25576295 [TBL] [Abstract][Full Text] [Related]
57. LncRNA-UCA1 exerts oncogenic functions in non-small cell lung cancer by targeting miR-193a-3p. Nie W; Ge HJ; Yang XQ; Sun X; Huang H; Tao X; Chen WS; Li B Cancer Lett; 2016 Feb; 371(1):99-106. PubMed ID: 26655272 [TBL] [Abstract][Full Text] [Related]
58. miR-21 predicts poor prognosis in patients with osteosarcoma. Ren X; Shen Y; Zheng S; Liu J; Jiang X Br J Biomed Sci; 2016 Oct; 73(4):158-162. PubMed ID: 27922432 [TBL] [Abstract][Full Text] [Related]
59. B7-H1 and B7-H3 are independent predictors of poor prognosis in patients with non-small cell lung cancer. Mao Y; Li W; Chen K; Xie Y; Liu Q; Yao M; Duan W; Zhou X; Liang R; Tao M Oncotarget; 2015 Feb; 6(5):3452-61. PubMed ID: 25609202 [TBL] [Abstract][Full Text] [Related]
60. Upregulation of serum miR-494 predicts poor prognosis in non-small cell lung cancer patients. Zhang J; Wang T; Zhang Y; Wang H; Wu Y; Liu K; Pei C Cancer Biomark; 2018; 21(4):763-768. PubMed ID: 29286916 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]